Lagevrio® (molnupiravir) 200 mg hard capsules – shelf life extension
MSD UK in agreement with the Medicines and Healthcare product Regulatory Agency (MHRA) has announced an extension to the shelf-life of of certain batches of Lagevrio® (molnupiravir) 200 mg hard capsules beyond the labelled expiry date by 6, 12 or 18 months. This extension is based on supportive stability data for Lagevrio® which has been approved by the MHRA.
Patients can continue to use the affected batches safely until their extended use by dates listed below. The expiry date extension does not apply to batches of Lagevrio® not listed in the table below.
| Batch number | Labelled Expiry Date (end of the month) |
Extended Use by Date (end of the month) |
| U035832, U035834, U035826, U035830, U035829, U035827 | December 2022 | June 2024 |
| CKFWW, CKFWT, CKFXB, U035259, U035349, U035403, U035575, U035580, U035584, U035723, U036097, U036227, U036303, U036096, U036063 | January 2023 | July 2024 |
| U038932, U038928, U039514, U038931, U039699, U038933, W003017, W001762, W002196, W002251, W002252, W003006, W003015, W001492, W001742, W001757, W001763, W002191, W002192, W002200, W002201, W002209, W003055, W003012 | February 2023 | August 2024 |
| U040071, U040082, U040308, U040300, W001764, U040316, W002566, W002577, W002582, W003430, W003111, W003431 | March 2023 | September 2024 |
| 2644400, 2620967, 2620965, 2620959, 2644399, W003434, W005862, W005866, W005869, W005872, W005873, W006344, W006347, W006351, W006360, W006363, W006353, W006354, W006793, W006365, W006369, W006358, W006794, W006945 | April 2023 | October 2024 |
| 2620971, 2620975, 2620973, 2620969, 2620977, 2698245, 2678932, 2698247 | May 2023 | November 2024 |
| W011781, W012460 | August 2023 | August 2024 |
| W007695, W008022, W007683, W007684, W007693 | October 2023 | October 2024 |
| W012394, W012403, W012408, W012538, W012585, W017279, 2698249 | November 2023 | November 2024 |
| 2689837, 2689839, 2689841, 2689845, 2689847, 2689851, 2843352, 2689855 | December 2023 | December 2024 |
| W031114, W031120, W031127 | August 2024 | February 2025 |
| W032935, W032936, W032940, W033244, W033245, W033246, W032594, W032598, W032911, W032934 | September 2024 | March 2025 |
Affected batches of Lagevrio® will be co-packed with a Dear Patient letter to notify patients of the extended use by dates. There is no need to remove the Patient Letter before passing the medicine to the patient. A hard copy of the Direct Healthcare Professional (DHCP) letter will also be included with pharmacy deliveries. While the extension applies to all affected batches, pharmacies are not expected to print additional Dear Patient Letters for stock already on the shelves.
Pharmacy teams should tell patients and caregivers about the extended use by date of the specified batches of Lagevrio®.
Lagevrio® is subject to additional monitoring identified by the black triangle ▼. Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card Scheme see www.mhra.gov.uk/yellowcard.
Company contact point: If you require further information please contact medicalinformationuk@msd.com or call MSD Medical Information services on 0208 154 8000.
